THIS TRIAL IS CLOSED. The trial completed enrollment on August 21, 2023.
This trial is testing whether a shorter course of radiation treatment for prostate cancer is safe and feasible. The trial uses MRI guidance to shape radiation around organs like the rectum and bladder, reducing the number of overall treatment days required. Men with low or intermediate risk prostate cancer who are willing to undergo MRI-guided radiation therapy and meet other requirements can enroll in the trial.
Patients are eligible if they are/have:
- Men aged 18 and older with histologically confirmed prostate cancer after prostatectomy with detectable PSA. PSA does not need to be detectable for men with pathologically node positive disease.
- KPS >=70
- Patient with no evidence of distant metastatic disease on PET/CT/MRI or bone scan < 9 months prior to enrollment. Patients with positive pelvic lymph nodes are eligible.
- Ability to receive MRI-guided radiotherapy.
- Equivocal evidence of metastatic disease outside the pelvis on standard imaging requires documented negative biopsy.
- Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire.